Nucala 100 MG/ML auto-injectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FGBR9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,932
Award facts
- Contract value 100% obligated
- $1,931.83 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $1,931.83 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of NUCALA 100 mg/mL auto-injectors. The award, issued on January 28, 2026, with an ultimate completion date of January 29, 2026, utilizes a firm fixed-price contract structure with no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA, the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical support to Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain since its SAM registration in 2001, demonstrating consistent performance across diverse therapeutic categories. The company's PPV-G GEN V prime vendor contract, awarded in November 2025 with a $499.999 billion ceiling and extending through December 31, 2036, authorizes DLA to issue delivery orders for branded and generic prescription drugs, biologics, and medical consumables. NUCALA, a biologic immunosuppressant agent, represents the type of specialized pharmaceutical product the vendor routinely supplies to support military medical operations, with delivery orders under this contract ranging from under $100 to exceeding $115,000 depending on specific clinical and operational requirements.
Quick answers
Who was awarded contract SPE2DR26FGBR9?
SPE2DR26FGBR9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FGBR9 worth?
The government has obligated $1,932 on SPE2DR26FGBR9.
Is contract SPE2DR26FGBR9 an order under another contract?
Yes. SPE2DR26FGBR9 is a delivery order under SPE2DR25D9315, an indefinite delivery contract.
Was contract SPE2DR26FGBR9 competed?
The extent of competition for SPE2DR26FGBR9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award